§ 17-26-104.9. Opioid Treatment for a Person in Custody – Definitions

1. A facility, whether operated by a governmental entity or private contractor, may make available opioid agonists and opioid antagonists to a person in custody with an opioid use disorder. The facility is strongly encouraged to maintain the treatment of the person throughout the duration of the person’s incarceration, as medically necessary.
2. Qualified medication administration personnel may, in accordance with a written physician’s order, administer opioid agonists and opioid antagonists pursuant to subsection (1) of this section.
3. A facility may contract with community-based health providers for the implementation of this section.
4. As used in this section, unless the context otherwise requires:
   1. “Facility” means:
      1. A local jail, as defined in section 17-1-102 (7);
      2. A multijurisdictional jail, as described in section 17-26.5-101; and
      3. A municipal jail, as authorized in section 31-15-401 (1)(j).
   2. “Opioid agonist” means a full or partial agonist that is approved by the federal food and drug administration for the treatment of an opioid use disorder.
   3. “Opioid antagonist” means naltrexone or any similarly acting drug that is not a controlled substance and that is approved by the federal food and drug administration for the treatment of an opioid use disorder.

Source: L. 2020: Entire section added, (HB 20-1017), ch. 288, p. 1423, § 2, effective September 14.